Supernus Pharmaceuticals CEO Sells $1.76M in Stock
Insider sale trims CEO's stake by 3.52% as analyst coverage remains mixed
Fred Alger Management Trims Stake in Xometry
The institutional investor reduced its holdings in the manufacturing technology company by 16.7% in the third quarter.
Eventide Asset Management Reduces Stake in Xometry
The investment firm lowered its holdings in the manufacturing technology company by 1.3% during the third quarter.
Mar. 11, 2026
Jefferies Financial Group Boosts Stake in Supernus Pharmaceuticals
Institutional investor increases ownership in specialty pharmaceutical company by 62% in Q3
Mar. 10, 2026
Victory Capital Management Reduces Stake in Supernus Pharmaceuticals
Institutional investor sells nearly 200,000 shares of specialty pharmaceutical company
Mar. 9, 2026
MacroGenics Reports Q4 Earnings
Biopharmaceutical company exceeds Wall Street expectations
Mar. 9, 2026
D. Boral Capital Reaffirms Buy Rating for OS Therapies
Analysts maintain positive outlook on biotech firm's prospects
Mar. 9, 2026
Blair William & Co. IL Boosts Xometry, Inc. Stake
Institutional investor increases holdings in the on-demand manufacturing platform company.
Mar. 6, 2026
John Marshall Bancorp Stock Drops 2.8%
Analysts Weigh In on Whether Investors Should Sell
Mar. 6, 2026
ARK Investment Reduces Xometry Stake by 30%
Institutional investor sells over 37,000 shares of the manufacturing technology company
Mar. 5, 2026
GW&K Investment Management Reduces Stake in Supernus Pharmaceuticals
The investment firm sold 184,268 shares of the specialty pharmaceutical company in the third quarter.
Mar. 3, 2026
Xometry Director Buys Nearly $50K in Stock
Katharine Weymouth increases stake in the manufacturing technology company
Mar. 2, 2026
OS Therapies Short Interest Surges 42%
Biopharmaceutical company sees significant increase in short positions on its stock.
Mar. 2, 2026
Xometry Director Buys $50K in Company Stock
Katharine Weymouth increases her stake in the manufacturing technology firm by over 50%
Mar. 2, 2026
Wall Street Zen Upgrades Supernus Pharmaceuticals to 'Strong-Buy'
Analysts cite positive outlook for the specialty pharmaceutical company's CNS therapies.
Feb. 28, 2026
Xometry CEO Sells Over $1.3 Million in Stock
Randolph Altschuler offloads nearly 32,000 shares as company's stock price declines
Feb. 28, 2026
Wedbush Cuts Xometry Price Target to $60
Analysts lower price target for on-demand manufacturing platform
Feb. 28, 2026
Wall Street Zen Upgrades Supernus Pharmaceuticals to Strong Buy
Analysts cite potential for the company's CNS therapies as key driver for upgrade.
We keep track of fun holidays and special moments on the cultural calendar — giving you exciting activities, deals, local events, brand promotions, and other exciting ways to celebrate.
